| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Basic Study |
| Article Title |
Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sylvie Lagaye, Sonia Brun, Jesintha Gaston, Hong Shen, Ruzena Stranska, Claire Camus, Clarisse Dubray, Géraldine Rousseau, Pierre-Philippe Massault, Jerôme Courcambeck, Firas Bassisi, Philippe Halfon and Stanislas Pol |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Institut National de la Santé et de la Recherche Médicale (INSERM, France) |
|
| personal support of Professor Jean-François Delfraissy as Director of the French Agency, Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) |
|
|
| Corresponding Author |
Sylvie Lagaye, PhD, DSc, Senior Scientist, Institut Pasteur, INSERM U1223, 25-28 rue du Dr Roux, 75015 Paris, France. sylvie.lagaye@inserm.fr |
| Key Words |
Host antiviral therapy; Hepatitis C virus; Tissue culture; Autophagy; Quinoline derivative |
| Core Tip |
Hepatitis C virus (HCV) infection (or spread) is a serious public health challenge counting approximately 170 million people that are chronically infected world-wide. Efficient interferon-free treatments with new direct acting antivirals are expected to cure more than 90% of HCV-infected patients but they are not available in all the countries. Autophagy machinery is required to initiate HCV replication. Host antiviral therapy is an additional option for the treatment of HCV infection. The new autophagy inhibitor GNS-396 demonstrated significant efficacy and additive activity in inhibiting HCV replication and might be an additional option to treat HCV infected individuals. |
| Publish Date |
2016-07-22 10:22 |
| Citation |
Lagaye S, Brun S, Gaston J, Shen H, Stranska R, Camus C, Dubray C, Rousseau G, Massault PP, Courcambeck J, Bassisi F, Halfon P, Pol S. Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. World J Hepatol 2016; 8(21): 902-914 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i21/902.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i21.902 |
